Re: Response of Aleukemic Granulocytic Sarcoma to All-trans-retinoic Acid Plus Interferon Alfa-2a

Fleming et al report on two patients treated with a regimen of continuous oral all-trans-retinoic acid (ATRA) at a dose of 150 mg/m2 per day for days 1-29 followed by the same ATRA regimen combined with subcutaneous interferon alfa-2a at 3 million units per day on days 30-58.

Saved in:
Bibliographic Details
Published inJNCI : Journal of the National Cancer Institute Vol. 89; no. 2; pp. 172 - 173
Main Authors Fleming, Gini F., Waggoner, S. E., Wu, S., Rotmensch, J., Conley, B. A.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 15.01.1997
Oxford Publishing Limited (England)
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Chemotherapy
Humans
Interferon alpha-2
Interferon-alpha - administration & dosage
Leukemia, Myeloid - blood
Leukemia, Myeloid - drug therapy
Recombinant Proteins
Sarcoma - blood
Sarcoma - drug therapy
Treatment Outcome
Tretinoin - administration & dosage
Tretinoin - blood
Online AccessGet full text

Cover

More Information
Summary:Fleming et al report on two patients treated with a regimen of continuous oral all-trans-retinoic acid (ATRA) at a dose of 150 mg/m2 per day for days 1-29 followed by the same ATRA regimen combined with subcutaneous interferon alfa-2a at 3 million units per day on days 30-58.
Bibliography:The study on which these patients were treated was supported in part by Public Health Service grant GCRC M01RR00055 from the National Center for Research Resources, National Institutes of Health, Department of Health and Human Services.
ark:/67375/HXZ-QFWM79GN-B
Correspondence to: Gini F. Fleming, M.D., Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S. Maryland Ave., MC 2115, Chicago, IL 60637-1470.
istex:FA1DE55C8449B5B3C343A26A90E0B6CA39945227
SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/89.2.172-a